Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
WALTHAM, Mass., Oct. 2, 2012 (GLOBE NEWSWIRE) -- TESARO, Inc. (Nasdaq:TSRO) announced today that the Investigational New Drug (IND) application for TSR-011, an orally available ALK inhibitor (targeted...
-
WALTHAM, Mass., Sept. 4, 2012 (GLOBE NEWSWIRE) -- TESARO, Inc. (Nasdaq:TSRO) today announced the appointment of Dr. Robert Martell as Chief Medical Officer. Dr. Martell is a practicing medical...
-
WALTHAM, Mass., Sept. 4, 2012 (GLOBE NEWSWIRE) -- TESARO, Inc. (Nasdaq:TSRO) announced today that Lonnie Moulder, Chief Executive Officer, and Mary Lynne Hedley, Ph.D., President and Chief Scientific...
-
WALTHAM, Mass., Aug. 29, 2012 (GLOBE NEWSWIRE) -- TESARO, Inc. (Nasdaq:TSRO) today announced that Lonnie Moulder, Chief Executive Officer, will be presenting at the Robert W. Baird 2012 Healthcare...
-
Key Rolapitant Clinical Trial Results Presented at ASCO and MASCC Meetings In-Licensed Niraparib, a Potentially First and Best-in-Class PARP Inhibitor Raised Over $86.8 Million in Gross...
-
WALTHAM, Mass., July 24, 2012 (GLOBE NEWSWIRE) -- TESARO, Inc. (Nasdaq:TSRO) announced today that the underwriters of its initial public offering have partially exercised their over-allotment option...
-
WALTHAM, Mass., July 19, 2012 (GLOBE NEWSWIRE) -- TESARO, Inc. (Nasdaq:TSRO) will announce its second quarter 2012 financial results on Thursday, July 26th, 2012, before the open of the U.S. financial...
-
WALTHAM, Mass., June 27, 2012 (GLOBE NEWSWIRE) -- TESARO, Inc. announced today the pricing of its initial public offering of 6,000,000 shares of its common stock at a price to the public of $13.50 per...